The Food and Drug Administration has accepted the Reasonable Expectation of Effectiveness section of Loyal’s conditional approval application for LOY-002, a drug designed to extend the healthy lifespan of senior dogs aged 10 years and older weighing at least 14 lb, the company said in 2024.

This decision marks a regulatory milestone for a longevity therapy for senior dogs, following an earlier RXE acceptance for LOY-001, which targets large- and giant-breed dogs that age faster than smaller breeds. This initiative comes at a time when large dog breeds face several common health issues, including hip and elbow dysplasia that can lead to significant pain and arthritis.

Celine Halioua, CEO of Loyal, described the scale of the problem the drug seeks to address, invoking breeds that illustrate extreme differences in longevity. “We’re looking at rottweilers, Great Danes, Bernese Mountain dogs that, on the extreme, will live nearly half the lifespan that is expected of a chihuahua or a miniature poodle,” she said. She noted that large- and giant-breed dogs often require specialized care to manage their unique health challenges effectively.

Loyal says its large-dog longevity candidates LOY-001 and LOY-003 focus on correcting overexpression of insulin-like growth factor 1 (IGF-1) and growth hormone in large dogs after maturity. This targeting is essential given that high IGF-1 levels in large breeds may contribute to aging-related diseases, emphasizing the need for preventive therapies.

Linda Rhodes, VMD, PhD and an animal health industry expert, framed the regulatory challenge the company is attempting. “Developing a treatment that will increase longevity by reducing age-associated disease is a new indication. No drug has ever been approved with such a claim, and pioneering a new indication through regulatory agencies requires an enormous amount of rigor and persistence,” she said. Importantly, the FDA’s approval process for veterinary drugs, while similar to that for humans, focuses on different scopes and scales, which adds to the complexity of securing approval.

The FDA provided support specifically for the Reasonable Expectation of Effectiveness section of Loyal’s filing, a step the company characterizes as pivotal in pursuing conditional approval. Loyal is the developer of LOY-001 and has publicly discussed regulatory milestones and planning on its website; the company statement is available on Loyal’s site.

Brennen McKenzie, director of veterinary medicine at Loyal, is listed among the company’s team working on the program.

Halioua also addressed questions about who the drug is for and its affordability. “This is not something for billionaires’ dogs only. We are currently doing the pricing sensitivity work but we’re talking to both veterinarians and pet parents,” she said. This accessibility is crucial, especially as pet owners seek to promote a healthy lifestyle through balanced diets and regular veterinary care, ensuring their dogs can benefit from innovative treatments.

Company materials cite the drug’s mechanism and the disproportionate IGF-1 levels in large breeds as the biological rationale for targeting those animals. The combination of biochemical targeting and the FDA’s acceptance of the Reasonable Expectation of Effectiveness section frames LOY-001 as an early entry in a new category of preventive longevity therapies for dogs.

The FDA’s action was announced on Nov. 28, 2023. Loyal is positioning LOY-002, along with LOY-001 and LOY-003, as part of a broader research and development program focused on canine longevity, and it has provided details about timelines and next steps on its website and in public statements.

Where things stand now: the FDA has accepted the RXE section of Loyal’s LOY-002 conditional approval application, following an earlier RXE acceptance for LOY-001; Loyal’s STAY trial for LOY-002 aims to enroll about 1,000 dogs; and the company currently projects conditional approval for LOY-002 around late 2025 and for LOY-001 and LOY-003 around 2027, while continuing regulatory work and outreach.

Source

Original reporting: view the original article.